Matthias König: Developing an Open Whole-Body PBPK/PD Digital Twin of Apixaban
Matthias König, Associate Professor of Pharmacoepidemiology and Data Science at University of Southern Denmark, shared a post on LinkedIn about a recent preprint, he and his colleagues co-authored, published in Preprints.org, adding:
“New preprint: ‘An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics.’
In this work, we developed an open whole-body PBPK/PD digital twin of the direct oral anticoagulant apixaban, linking drug exposure to anticoagulation-related pharmacodynamic endpoints, including INR, PT, mPT, aPTT, and anti-Xa activity.
The model was built and evaluated using data from 35 curated clinical PK/PD studies, covering diverse dosing regimens and clinically relevant scenarios, including renal and hepatic impairment, food intake, and body weight effects.
It captures apixaban pharmacokinetics and pharmacodynamics across these populations and provides a reusable framework for personalised anticoagulant therapy.
A key focus was reproducibility and openness: all models, simulation workflows, documentation, and curated datasets are openly available and FAIR-compliant, enabling transparent reuse, independent verification, and future extension.
The work was developed as part of the Berlin University Alliance (BUA) X-Student Research Group ‘Digital Twins in Action:
Optimizing Direct Oral Anticoagulant Use’, funded by the Bundesministerium für Bildung und Forschung (BMBF) and the State of Berlin as part of the Excellence Strategy of the Federal and State Governments.”
Title: An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics
Authors: Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 27, 2026, 03:23Massimo Martino: VEN-DEC-GITMO – Advancing AML Treatment in Older Patients
-
Sep 27, 2026, 03:08Arrigo Francesco Giuseppe Cicero: Why Earlier LDL-C Lowering May Matter in Cardiovascular Prevention
-
Sep 27, 2026, 02:51Veronique Witko-Sarsat: Thromboinflammation at the 17th World Congress of Inflammation
-
Sep 27, 2026, 01:45Jin-Xiong She: Functional Iron Deficiency in the Setting of Chronic Inflammation
-
Sep 27, 2026, 01:44Crystal Karakochuk: Scientific Reports Launches New Collection on Iron Deficiency and Anemia
-
Sep 27, 2026, 01:44Arielle Nylander: National Expertise at the Center of Maternal Anemia Action
-
Sep 27, 2026, 01:43Muhammad Ans: Emerging Trends and Disparities in PE-Related Mortality Among Patients With AF
-
Sep 26, 2026, 18:01Kalyan Roy: Blood Group Chimerism as a Rare Cause of ABO Discrepancy
-
Sep 26, 2026, 17:34Arwa Z. Al-Riyami: Join ISBT and Advance Your Career